Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Service for Surveillance in Healthcare, receiving the GMP certificate from the Eurasian Economic Union, which enhances its competitiveness in the active pharmaceutical ingredient market and supports the promotion of Teriparatide in the region [1] Group 1 - Hubei Jianxiang underwent an inspection from July 30 to August 1, 2025, by the Russian Federal Ministry of Industry and Trade's drug inspection agency [1] - The company received the GMP certificate, confirming compliance with the quality system for active pharmaceutical ingredient production recognized by Russia and the Eurasian Economic Union [1] - The certification validates the maturity of Hubei Jianxiang's production control, quality management, and public system assurance, strengthening its core competitiveness in the active pharmaceutical ingredient sector [1] Group 2 - The GMP certification provides essential qualification support for the market promotion of Teriparatide active pharmaceutical ingredients in the region [1] - This achievement is expected to enhance the company's influence in international markets and positively contribute to future operational performance growth [1]